André, RosárioJacob, Justin2025-04-022025-04-022025-01-242025-01-24http://hdl.handle.net/10362/181869This equity research report, prepared as part of Nova SBE’s Field Lab by Justin Jacob and Rupert Schuler, evaluates Johnson & Johnson (JNJ). Our valuation estimates a share price of $183, indicating the stock is undervalued compared to its December 13, 2024 market price of $146.62. A detailed relative valuation and sensitivity analysis across four scenarios support this conclusion. The report considers JNJ’s operational resilience, ongoing litigations, and macroeconomic factors, providing a balanced assessment of internal and external influences on the company’s intrinsic value.engDrugsResearch & DevelopmentValuationLitigationsmaster thesis203926404